331 related articles for article (PubMed ID: 19483089)
1. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
Mena-Ramírez JP; Salazar-Páramo M; Dávalos-Rodríguez IP
Gac Med Mex; 2008; 144(5):449-51. PubMed ID: 19043967
[TBL] [Abstract][Full Text] [Related]
5. An update on methotrexate.
Braun J; Rau R
Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
[TBL] [Abstract][Full Text] [Related]
6. The pharmacogenetics of methotrexate.
Hider SL; Bruce IN; Thomson W
Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
[TBL] [Abstract][Full Text] [Related]
7. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
Stamp L; Roberts R; Kennedy M; Barclay M; O'Donnell J; Chapman P
Biomed Pharmacother; 2006 Dec; 60(10):678-87. PubMed ID: 17071051
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
Dervieux T
J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
[No Abstract] [Full Text] [Related]
9. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
10. [Modern therapy of rheumatoid arthritis. Joint destruction can be delayed].
Neumaier J
MMW Fortschr Med; 2008 Apr; 150(14):14. PubMed ID: 18488571
[No Abstract] [Full Text] [Related]
11. Is there a need for new therapies for rheumatoid arthritis?
Fleischmann RM
J Rheumatol Suppl; 2005 Feb; 73():3-7; discussion 29-30. PubMed ID: 15693109
[TBL] [Abstract][Full Text] [Related]
12. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
Scherer HU; Dörner T; Burmester GR
Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of therapies in rheumatoid arthritis.
Ranganathan P
Drugs Today (Barc); 2005 Dec; 41(12):799-814. PubMed ID: 16474855
[TBL] [Abstract][Full Text] [Related]
14. Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.
Owen SA; Lunt M; Hider SL; Bruce IN; Barton A; Thomson W
Arthritis Rheum; 2010 Dec; 62(12):3827-9. PubMed ID: 20848569
[No Abstract] [Full Text] [Related]
15. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
[TBL] [Abstract][Full Text] [Related]
16. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
17. Unmet needs in rheumatoid arthritis.
Bykerk V
J Rheumatol Suppl; 2009 Jun; 82():42-6. PubMed ID: 19509330
[TBL] [Abstract][Full Text] [Related]
18. Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression.
van Roon JA; Jacobs K; Verstappen S; Bijlsma J; Lafeber F
Ann Rheum Dis; 2008 Jul; 67(7):1054-5. PubMed ID: 18556451
[No Abstract] [Full Text] [Related]
19. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra).
Bansard C; Lequerré T; Derambure C; Vittecoq O; Hiron M; Daragon A; Pouplin S; Daveau M; Boyer O; Tron F; Le Loët X; Salier JP
Rheumatology (Oxford); 2011 Feb; 50(2):283-92. PubMed ID: 21059672
[TBL] [Abstract][Full Text] [Related]
20. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
Riksen NP; Rongen GA; Smits P; van Riel P; Barrera P
Arthritis Rheum; 2007 Feb; 56(2):694; author reply 694-5. PubMed ID: 17265507
[No Abstract] [Full Text] [Related]
[Next] [New Search]
